SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares are under pressure after earnings beat expectations and the company raised its full-year EPS outlook, as traders focus on planned workforce cuts and restructuring costs; a slight revenue shortfall and rising expenses also drew scrutiny. Some investors argue the strong results and guidance outweigh those concerns.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is rallying with cybersecurity peers as AI-related vulnerabilities and autonomous agents sharpen demand for identity and AI security, with traders pointing to the companys role in securing AI identities. Bulls see the theme supporting growth, while skeptics argue the sharp run-up is difficult to justify given Oktas modest growth and high valuation.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSkys expanded seven-figure Gen-3 contract with an international defense partner is drawing attention, but traders are debating why the shares remain weak despite contract wins. Some see the deals as evidence of execution, while others are focused on the steep decline and upcoming Q3 results.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

A sharp rally and unusually heavy bullish call activity ahead of earnings are driving attention, with bulls pointing to Snaps Specs AR glasses and a proposal to sell an outside stake in the unit as potential catalysts. Others question whether the enthusiasm can last, citing ad-market concerns and the risk that options-driven momentum fades.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare shares are drawing attention as cybersecurity stocks rally around the PHP2Shell vulnerabilities, with traders viewing Cloudflares web application firewall as a potential beneficiary because it can block exploit traffic. The move has prompted bullish momentum trading, while some traders warn against chasing the sharp gain or focus on the stocks valuation.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits upcoming earnings report is the main focus, with traders watching for evidence that ad growth can offset concerns about user trends and the lack of new AI data-licensing deals. Sentiment is split between bulls citing improving ad monetization and business fundamentals, and frustrated bears pointing to the stocks weak, choppy performance and questioning whether earnings can revive it.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is drawing attention ahead of the CTX310 Phase 1b presentation at the AHA meeting, with traders focused on whether the in-vivo gene-editing data could validate the cardiovascular program. Reactions are mixed: some are positioning around the readout, while others are concerned about the stocks persistent range-bound trading and the CFO transition, which some view as unsettling despite reports of an orderly handoff.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is rising with cybersecurity peers as AI-related vulnerabilities and escalating threat reports renew expectations for security spending; an Evercore channel survey cited by traders also points to firming enterprise budgets. The reaction is broadly bullish, though some traders question whether the sectors sharp rally is justified by already-stretched valuations.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

FRVO is drawing attention amid a steep selloff and debate over a Morpheus short report questioning Fervos geothermal performance, including water recovery and project economics; investors also cite transmission constraints and potential IPO-related selling. Bears see serious execution risks, while bulls dismiss the report as biased and point to Cape Stations first power and Google contracts as evidence of progress.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubriks strong quarterly results and raised outlook are driving renewed attention, but shares initially sold off as investors focused on slower cloud net-new ARR growth and cautious second-half guidance. The community is split between treating the pullback as a buying opportunity and arguing that elevated expectations and concerns about management guidance could keep pressure on the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromePR...

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.   New York, NY – October 21, 2026 – Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the […]
The post Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market appeared first on Financial News Media.

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's DiseasePR NewswireSAN DIEGO, Oct. 20, 2026 SAN DIEGO, Oct. 20, 2026 /PRNewswire...

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaPR NewswireSAN DIEGO, Oct. 16, 2026...

Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

NBIX vs. SDZNY: Which Stock Is the Better Value Option?

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial ResultsPR NewswireSAN DIEGO, Oct. 12, 2026Conference Call and Webcast Scheduled for Monday, November 2SAN...

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference Neurocrine Biosciences to Present Research Advancing Understanding of...

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Neurocrine Biosciences gained VYKAT XR through its $2.9-billion acquisition of Soleno Therapeutics, completed in May.</li><li>FPWR noted seven reported deaths and more than 100 reports of serious adverse events involving heart or breathing issues in patients taking the drug.</li><li>In August 2025, short-seller Scorpion Capital published a lengthy report alleging serious risks of fluid buildup, pulmonary edema, and heart failure with Vykat XR use, along with concerns about clinical-trial data.</li></ul><p>Shares of Neurocrine Biosciences closed 3% lower on Wednesday and further slipped 1% after-hours after the Foundation for Prader-Willi Research (FPWR) recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on its drug VYKAT XR for fluid retention and related heart or breathing problems.</p><p>FPWR blog from Monday outlines practical steps for real-world use of the drug, the first FDA-approved treatment for extreme hunger (hyperphagia) in PWS patients aged four and older. FPWR further advises families to review the full prescribing information and consult PWS specialists so the potential benefits of reduced hyperphagia can be weighed carefully against the risks.</p><p>Since Vykat XR’s March 2025 launch, more than 800 people have received prescriptions. The medicine can help control appetite but may cause edema that, in some cases, has been linked to serious complications, according to experts.</p><h2 class="st-heading-2">Heightened Focus On Safety Signals</h2><p>FPWR noted seven reported deaths and more than 100 reports of serious adverse events involving heart or breathing issues in patients taking the drug. Many of those individuals already had obesity, multiple medications, or untreated sleep apnea. The foundation stresses that PWS itself carries elevated baseline risks, so a direct link is not always clear. Still, it recommends safety tests before starting treatment, ongoing checks for swelling or breathing changes, and care from physicians experienced with the syndrome.</p><h2 class="st-heading-2">Neurocrine Adds Vykat XR</h2><p>Neurocrine Biosciences gained VYKAT XR through its $2.9 billion acquisition of Soleno Therapeutics, completed in May. Soleno developed and launched the once-daily pill.</p><p>While still under Soleno, the drug faced scrutiny. In August 2025, short-seller Scorpion Capital published a lengthy report alleging serious risks of fluid buildup, pulmonary edema, and heart failure, along with concerns about clinical-trial data. The following month, Soleno disclosed the death of a 17-year-old patient who had been taking the medicine, though the company and treating physician assessed the death as unrelated to the drug. Investor lawsuits later claimed Soleno had downplayed fluid-retention signals.</p><h2 class="st-heading-2">Broader Impact On PWS Pipeline</h2><p>Safety worries have slowed other PWS programs. Aardvark Therapeutics paused its late-stage trial of ARD-101 last year after cardiac observations in healthy volunteers, and the FDA later placed a clinical hold. Years earlier, Zafgen ended development of beloranib after patient deaths linked to blood clots. Acadia Pharmaceuticals also discontinued its candidate after a failed efficacy study.</p><h2 class="st-heading-2">How Did NBIX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around NBIX stayed within ‘bearish’ territory while message volume stayed at ‘normal’ levels.</p><p>A Stocktwits user highlighted that no clear link has been established between the drug’s use and the negative side effects.</p><p><stembedurl>https://www.stocktwits.com/GoIrish1776/message/661644013</stembedurl></p><p>“I always thought vykat/soleno was a bad drug and investment,” another user wrote.</p><p><stembedurl>https://www.stocktwits.com/outlawinvestor1/message/661718610</stembedurl></p><p><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://stocktwits.comhttps://stocktwits.com/symbol/NBIX/symbol/NBIX">NBIX stock</a> has gained 10% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-cars-facing-more-demand-than-stock-buyers-face-extended-waits-for-base-model-3-model-y-and-cybertruck/cZo8SNZRJWH">Tesla Cars Facing More Demand Than Stock? Buyers Face Extended Waits For Base Model 3, Model Y And Cybertruck</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Neurocrine Biosciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems.

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Safety Warnings

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems. 


American Century ETF Trust - Avantis U.S. Equity ETF

JPMorgan Active Growth ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$142.70
Prev Close	$143.29
Open	$142.74
Dividend Yield	0.00%
50-Day Moving Average	$147.43
Beta	0.74
Avg. Volume	1.23M
PE Ratio	20.91

52-Week High	$186.12
52-Week Low	$122.14
Market Capitalization	$14.51B
EPS (Annual)	$4.67
Price to Book	3.93
Revenue Per Employee	$1.43M

Feed

News

Sentiment

Earnings

Fundamentals

Info

NBIX Fundamentals